236 
Market Cap
As of July 22, 2011: $219,492,000.00
Stock Chart
Chemgenex - 30 Day Poll
Recent BLOGS About Chemgenex Add New
 |
Chemgenex - beaten down and will it move
Chemgenex was beaten down after the first FDA feedback but has now started to move a little. Given t… Read more
|
Latest Company News
There are no news articles to display.
Website
Videos related to Chemgenex
Company Profile
ChemGenex is based in Melbourne, Australia and Menlo Park, California. ChemGenex is developing medicines for the treatment of cancer. The company focuses on validated targets in diseases with genetic components, to try and bring targeted therapeutics.
Product Candidates:
Omacetax ine mepesuccinate (formerly known as Ceflatonin®, homoharringtonine or HHT), an investigational small molecule agent, is in Registration-Directed clinical trials to evaluate its safety and potential efficacy for the treatment of chronic myelogenous leukemia (CML) patients with the T315I point mutation who are resistant to Gleevec®. Omacetaxine is also in Phase 2 clinical trials in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS). Omacetaxine induces the death of cancerous cells through the process of apoptosis, or programmed cell death. This drug has demonstrated promising clinical activity in CML patients who have developed resistance to Gleevec® (imatinib mesylate) and other tyrosine kinase inhibitors, and may offer new options for the increasing number of CML patients who are developing resistance to tyrosine kinase inhibitors.
Quinamed® (amonafide dihydrochloride), is in a Phase 2 trial for the treatment of hormone refractory prostate cancer. In a Phase 1 study to determine the best dose based on a patient's genotype, Quinamed® generated responses in patients with refractory prostate, ovarian and gastric tumors. In Phase 2, patients are genotyped prior to therapy to determine how quickly they metabolize the drug and are then assigned a specific dose based on their metabolic profile, or genotype. The goal is to maximize Quinamed®'s therapeutic potential while minimizing drug side-effects.
Cash Position:
The company had cash of $18 million at January 2011.
Income for the half-year ended 31 December 2010 was $426,499 (2009: $17,707,084).
Upcoming Events:
- The completion of a rolling submission to the U.S. Food and Drug Administration (FDA) of an NDA for omacetaxine
Quinamed® (amonafide dihydrochloride), is in a Phase 2 trial for the treatment of hormone refractory prostate cancer. In a Phase 1 study to determine the best dose based on a patient's genotype, Quinamed® generated responses in patients with refractory prostate, ovarian and gastric tumors. In Phase 2, patients are genotyped prior to therapy to determine how quickly they metabolize the drug and are then assigned a specific dose based on their metabolic profile, or genotype. The goal is to maximize Quinamed®'s therapeutic potential while minimizing drug side-effects.
Cash Position:
The company had cash of $18 million at January 2011.
Income for the half-year ended 31 December 2010 was $426,499 (2009: $17,707,084).
Upcoming Events:
- The completion of a rolling submission to the U.S. Food and Drug Administration (FDA) of an NDA for omacetaxine
- The completion of a submission to the European Medicines Agency (EMEA) of an MAA for omacetaxine
Possible Competition & Similar Companies:
- Epicept in Phase II for AML
- Vion Phase III for AML
Some Key people in the company:
Dr George Morstyn MBBS BMedSci MAICD PhD FRACP (Non-executive Director). Dr. Morstyn has substantial clinical, research and commercial experience in biotechnology and oncology. He was Senior Vice President of Development and Chief Medical Officer at Amgen Inc from 1991 to 2002 (the world's largest Biotech company based in California). He has been a Director of a number of other high profile Australian biotechnology companies and chairman of the Board of GBS Ventures (a Venture capital firm).
Possible Competition & Similar Companies:
- Epicept in Phase II for AML
- Vion Phase III for AML
Dr George Morstyn MBBS BMedSci MAICD PhD FRACP (Non-executive Director). Dr. Morstyn has substantial clinical, research and commercial experience in biotechnology and oncology. He was Senior Vice President of Development and Chief Medical Officer at Amgen Inc from 1991 to 2002 (the world's largest Biotech company based in California). He has been a Director of a number of other high profile Australian biotechnology companies and chairman of the Board of GBS Ventures (a Venture capital firm).
Dr Greg Collier BSc (Hons) PhD (CEO and Managing Director). Dr. Collier joined ChemGenex in 2000 as Chief Operating Officer and was promoted to CEO in June 2002. He has more than 21 years experience spanning commercial, operational, clinical and scientific aspects of pharmaceutical research and development.
Dr Geoff Brooke MBBS MBA (Non-executive Director) Dr. Brooke is Managing Director of GBS Venture Partners. He was formerly President of Medvest Inc, a US-based early stage venture capital group he co-founded with Johnson & Johnson. Dr. Brooke’s experience includes company formation and acquisitions, as well as public listings on both NASDAQ and ASX. Dr. Brooke is a Director of Sunshine Heart Inc and a former Director of CogState.
The consolidated entity employed 16 employees as at 30 June 2009.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use